Good Scientist, Bad Interviewer?
How HR and hiring managers can improve interview outcomes to find objectively good scientific talent. It’s Tuesday morning. As the hiring manager for your biopharma company, you’re expecting a scientist to show up to an 8:30am interview. You get a call from the front...
Biotech: Where Failure is Likely, Money Is Fleeting, and Layoffs are Inevitable
With clinical trials failing at least 90% of the time, here are current trends in the industry’s investment and hiring front. Clinical drug development is notoriously difficult. It is expensive, takes over a decade, and has an extremely high rate of failure—90% or...
The Inside Scoop on Unemployment Trends in Biopharma
Navigating the Complex Landscape of Biopharma Employment After a decade at Pfizer, immunologist Mary Sutton was laid off in February. Sutton (not her real name) has been looking for another mid-level executive position in new drug development since getting the WARN...
Employment Scams – what to look out for, and steps your company can take to fight back
It’s not just the application process that attracts bad actors as highlighted in previous article, “The Recruiter & The Thief” not everyone who applies is interested in the role, some are interested in stealing IP or strategic insights. Employment...Journal Articles
-
-
Good Scientist, Bad Interviewer?
Structured interviews and setting aside first impressions can help biotech hiring managers uncover talented but reserved candidates, ensuring strong scientists aren't overlooked due to interview style or first impressions. Shifting focus to “screening in” candidates promotes a more accurate assessment of both technical and soft skills.
Categories: Issue 4: Q4 2024
-
Backdoor References in Recruitment: Insight or Invasion?
Backdoor references can offer valuable insights into a candidate's skills and work ethic beyond their formal references, but hiring managers must handle them with care to ensure credibility and confidentiality. These informal checks should complement structured interviews rather than serve as the primary assessment tool.
Categories: Issue 4: Q4 2024
-
Biotech: Where Failure is Likely, Money Is Fleeting, and Layoffs are Inevitable
Clinical drug development is costly and has a failure rate over 90%, necessitating significant external funding for small companies. As mergers and acquisitions increase amid fierce competition and patent expirations, ongoing layoffs create opportunities for organizations to acquire talent.
Categories: Issue 4: Q4 2024
-
In Person-Interviewing: A Relic of the Past?
Biotech talent acquisition has increasingly embraced virtual interviews, yet many professionals stress the importance of in-person assessments for cultural fit. A blended approach of virtual and face-to-face interviews, along with behavioral evaluations, is crucial for identifying the best candidates.
Categories: Issue 4: Q4 2024
